Aspire Biopharma Holdings, Inc.
ASBP
$0.4871
-$0.0205-4.04%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 363.78% | 8.27% | 80.47% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 270.38% | 7.31% | 51.20% | ||
| Operating Income | -270.38% | -7.31% | -51.20% | ||
| Income Before Tax | -270.38% | -7.31% | -51.20% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -271.91% | -7.31% | -51.20% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -271.91% | -7.31% | -51.20% | ||
| EBIT | -270.38% | -7.31% | -51.20% | ||
| EBITDA | -- | -- | -- | ||
| EPS Basic | -- | -- | -- | ||
| Normalized Basic EPS | -- | -- | -- | ||
| EPS Diluted | -- | -- | -- | ||
| Normalized Diluted EPS | -- | -- | -- | ||
| Average Basic Shares Outstanding | -- | -- | -- | ||
| Average Diluted Shares Outstanding | -- | -- | -- | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||